The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: May 2024: The following drug classes/subclass will be reviewed:

a. Insulins – Subclass: Basal

Basaglar Kwikpen U-100

Basaglar Tempo Pen U-100

Insulin Degludec

Insulin Degludec Pen (U-100)

Insulin Degludec Pen (U-200)

Insulin Glargine

Insulin Glargine Solostar

Insulin Glargine-YFGN

Lantus

Lantus Solostar

Levemir

Levemir Flexpen

Levemir Flextouch

Rezvoglar Kwikpen

Semglee

Semglee (YFGN)

Semglee (YFGN) Pen

Semglee Pen

Toujeo Max Solostar

Toujeo Solostar

Tresiba

Tresiba Flextouch U-100

Tresiba Flextouch U-200

b. Insulins – Subclass: Rapid-Acting Agents

Admelog

Admelog Solostar

Afrezza

Apidra

Apidra Solostar

Fiasp

Fiasp Flextouch

Fiasp Penfill

Humalog

Humalog Junior Kiwkpen

Humalog Kwikpen U-100

Humalog Kwikpen U-200

Humalog Tempo Pen U-100

Humulin R

Insulin Aspart

Insulin Aspart Flexpen

Insulin Aspart Penfill

Insulin Lispro

Insulin Lispro Junior Kwikpen

Insulin Lispro Kwikpen U-100

Lyumjev

Lyumkev Kwikpen U-100

Lyumjev Kwikpen U-200

Lyumjev Tempo Pen U-100

Novolog

Novolog Flexpen

Novolog Penfill

c. Weight Loss Agents – Subclass: NA

Adipex-P

Contrave

Lomaira

Orlistat

Qsymia

Saxenda

Wegovy

Xenical

Zepbound

The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9201.

Pre-proposal teleconference is on January 31, 2024, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.